Clinical trials: Plaque Control
Psoriasis
A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp
This was a Phase IV randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of subcutaneous efalizumab in adult patients (18 years of age and older) with chronic moderate to severe plaque…
- Trial name
- SCALP (NCT00669214)
- Testing
- efalizumab
- Volunteers
- 89 people
- Sponsor
- Genentech, Inc.
Psoriasis
Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis
The purpose of this study is to evaluate the efficacy and safety of two dosing regimens of QRX-101 ointment (75 mcg/g QD and 75mcg/g BID) in the treatment of plaque-type psoriasis when applied topically twice daily for 8 weeks
- Trial name
- NCT00373516
- Testing
- QRX-101 75 mcg/g ointment applied QD, QRX-101 75 mcg/g ointment applied BID
- Where
- 12 sites in United States
- Volunteers
- 150 people
- Sponsor
- QuatRx Pharmaceuticals Company
Psoriasis
A Phase I Study to Assess Novel Cream in a Psoriasis Plaque Test
The purpose of this study is to investigate dose-response relationship, antipsoriatic efficacy and safety of different concentrations of topical formulations with AN2728 in subjects with psoriasis vulgaris.
- Trial name
- NCT00763204
- Testing
- AN2728 Cream, 2%, AN2728 Cream, 1%, AN2728 Cream, 0.3%
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Pfizer
Periodontal Disease
Study of Colonization of Strains L.Plantarum and L.Brevis in the Product AB-DENTALAC Chewing Gum
Study will follow a randomized, double-blind, placebo-controlled design with two groups in parallel,N of 40 patients in 6 weeks of follow up for the evaluation of two different posology models (daily consumption of probiotic gum…
- Trial name
- AB-GUM-2016 (NCT03540498)
- Testing
- AB-DENTALAC [Probiotics (study)]
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AB Biotics, SA
Dental Plaque, Oral Hygiene
Efficacy of Manual Toothbrushes in Removing Dental Plaque
This clinical methodology development study will evaluate the plaque removal efficacy of four marketed manual toothbrushes, with differing bristle types and brush head designs, in healthy dentate participants.
- Trial name
- NCT04025684
- Testing
- Oral B Indicator 123, Dr Best Original, Dr Best Multi Expert
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Periodontal Diseases, Periodontitis
Home Use of Dual-light Photodynamic Therapy for Chronic Periodontitis
This early-stage research is designed to determine the efficacy of the Lumoral method in chronic periodontitis patients. Improved supragingival plaque control can help to also sustain the subgingival plaque management in the long…
- Conditions
- Periodontal Diseases, Periodontitis, Plaque, Dental, Plaque Induced Gingivitis
- Trial name
- NCT05425784
- Testing
- Lumoral treatment, Standard oral hygiene self care
- Where
- 3 sites in Finland
- Volunteers
- 41 people
- Sponsor
- Koite Health Oy
Chronic Plaque Psoriasis, Moderate to Severe Nail Psoriasis
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis
- Trial name
- NCT03897075
- Testing
- Tildrakizumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 99 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Psoriasis
ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis
This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.
- Trial name
- NCT01208090
- Testing
- ACT-128800
- Where
- 67 sites in Austria, Belgium and 15 more
- Volunteers
- 326 people
- Sponsor
- Actelion
Inhibition of Plaque Formation (by Gingivitis-Index ≤1.5)
Study to Assess the Inhibition of Plaque Formation in Subjects With a Gingival Index ≤1.5
The objective of the study is to demonstrate the superiority of 0.1% octenidine mouthwash (Octenidin Mundspüllösung, OML) to placebo (PLAC) in the inhibition of plaque formation.
- Trial name
- NCT03322124
- Testing
- Octenidinedihydrochlorid
- Where
- 3 sites in Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Schülke & Mayr GmbH
Peyronie's Disease
Study of AA4500 in the Treatment of Peyronie's Disease
This study is a Phase 3, double-blind, randomized, placebo-controlled study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Approximately 300 (200 AA4500 and 100 placebo) men will be randomized.
- Trial name
- NCT01221623
- Testing
- AA4500
- Where
- 34 sites in United States, Australia
- Volunteers
- 418 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Psoriasis
Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis
The primary objective of this study is to compare the effects on disease activity, in the absence of systemic psoriasis therapy, of 4 mg/kg MEDI-522 versus placebo administered weekly by SC injection for 12 weeks.
- Trial name
- NCT00192517
- Testing
- MEDI-522
- Where
- 20 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- MedImmune LLC
Plaque Psoriasis
A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis
This first in human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-06826647 in healthy subjects and subjects with plaque psoriasis.
- Trial name
- NCT03210961
- Testing
- PF-06826647 tablet, PF-06826647 oral suspension
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Pfizer
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)
This study is being conducted to evaluate the efficacy and safety/tolerability of subcutaneous tildrakizumab (MK-3222), followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic…
- Trial name
- reSURFACE 1 (NCT01722331)
- Testing
- Tildrakizumab 200 mg, Tildrakizumab 100 mg
- Volunteers
- 772 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Psoriasis
A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.
- Trial name
- NCT03535194
- Testing
- Mirikizumab, Secukinumab
- Where
- 178 sites in United States, Argentina and 14 more
- Volunteers
- 1,484 people
- Sponsor
- Eli Lilly and Company
Psoriasis
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01241591
- Testing
- CP 690,550 5 mg, CP 690,550 10 mg, Etanercept 50 mg
- Where
- 122 sites in Argentina, Austria and 24 more
- Volunteers
- 1,101 people
- Sponsor
- Pfizer
Moderate Plaque Psoriasis
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis
The purpose of this study is to evaluate the efficacy of guselkumab compared to an inactive drug in participants with low body surface area moderate plaque psoriasis and special site involvement.
- Trial name
- SPECTREM (NCT06039189)
- Testing
- Guselkumab
- Where
- 64 sites in United States, Canada
- Volunteers
- 338 people
- Sponsor
- Janssen Research & Development, LLC
Primary Hypercholesterolemia or Mixed Dyslipidemia
Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.
The purpose of this study was to evaluate the efficacy and safety of inclisiran as a monotherapy in Chinese adults with low or moderate atherosclerotic cardiovascular disease (ASCVD) risk and elevated low-density lipoprotein…
- Trial name
- V-Mono China (NCT05888103)
- Testing
- Inclisiran
- Where
- 28 sites in China
- Volunteers
- 207 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Intervention Study to Evaluate a Probiotic in Mild to Moderate Psoriasis Patients
This study evaluates the efficiency of a probiotic as a coadjuvant in the conventional treatment of mild to moderate plaque psoriasis.
- Trial name
- NCT02576197
- Testing
- Probiotic
- Where
- Spain
- Volunteers
- 98 people
- Sponsor
- Biopolis S.L.
Cardiovascular Disease
A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events
This study is designed to evaluate whether the adjuvanted recombinant zoster vaccine (RZV) or the adjuvanted respiratory syncytial virus PreFusion protein 3 (RSVPreF3) vaccine can attenuate the progression of coronary plaque in…
- Trial name
- NCT07712380
- Testing
- Adjuvanted RZV vaccine, Adjuvanted RSVPreF3 vaccine
- Volunteers
- 450 people
- Sponsor
- GlaxoSmithKline
Plaque Psoriasis
Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The primary objectives of the study are: To evaluate the safety and tolerability of three dose levels of MT-1303 in subjects with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01987843
- Testing
- MT-1303-Low, MT-1303-Middle, MT-1303-High
- Where
- 52 sites in Bulgaria, Estonia and 6 more
- Volunteers
- 142 people
- Sponsor
- Tanabe Pharma Corporation